Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 33Sarcoma 2Genitourinary 2CNS 1

Conditions

Oligodendroglioma 1Melanoma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiosurgery 22Nivolumab 21Ipilimumab 19pembrolizumab 15Temozolomide 11dabrafenib 10binimetinib 10encorafenib 8Cyclophosphamide 8trametinib 7Magnetic Resonance Spectroscopy 7Bevacizumab 6fludarabine 5cobimetinib 5Specimen Handling 5CTLA-4 Antigen 5fludarabine phosphate 3aldesleukin 3Vemurafenib 3Thalidomide 3Paclitaxel 3Oxaliplatin 3Interleukin-2 3Gemcitabine 3Drug Therapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3ulixertinib 2tovorafenib 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Introns × CNS × Clear all
NCT00498979 2020-07-24

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

Case Comprehensive Cancer Center

Phase 1 Completed
22 enrolled
CNSDermatologicSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡